JP2017519028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519028A5 JP2017519028A5 JP2016575073A JP2016575073A JP2017519028A5 JP 2017519028 A5 JP2017519028 A5 JP 2017519028A5 JP 2016575073 A JP2016575073 A JP 2016575073A JP 2016575073 A JP2016575073 A JP 2016575073A JP 2017519028 A5 JP2017519028 A5 JP 2017519028A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- severe hypertriglyceridemia
- compound
- methylphenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- 206010060749 Type I hyperlipidaemia Diseases 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 14
- 229940124597 therapeutic agent Drugs 0.000 claims 14
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 5
- JWHYSEDOYMYMNM-QGZVFWFLSA-N 2-[4-[(2r)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C([C@@H](OCC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(C(F)(F)F)C=C1 JWHYSEDOYMYMNM-QGZVFWFLSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 3
- SBZKOWAPPRXYGA-XRIGFGBMSA-N (2s)-2,6-diaminohexanoic acid;dihydrate Chemical compound O.O.NCCCC[C@H](N)C(O)=O SBZKOWAPPRXYGA-XRIGFGBMSA-N 0.000 claims 1
- 206010060755 Type V hyperlipidaemia Diseases 0.000 claims 1
- 238000002617 apheresis Methods 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 101000785223 Crocosmia x crocosmiiflora Myricetin 3-O-glucosyl 1,2-rhamnoside 6'-O-caffeoyltransferase AT1 Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- GXALXAKNHIROPE-QAQDUYKDSA-N chembl2364624 Chemical compound C1C[C@@H](CC(=O)O)CC[C@@H]1C1=CC=C(C=2N=CC(NC=3C=NC(=CC=3)C(F)(F)F)=CC=2)C=C1 GXALXAKNHIROPE-QAQDUYKDSA-N 0.000 description 1
- 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 229950002887 pradigastat Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462017444P | 2014-06-26 | 2014-06-26 | |
| US62/017,444 | 2014-06-26 | ||
| PCT/US2015/037596 WO2015200580A1 (en) | 2014-06-26 | 2015-06-25 | Treatment of severe hypertriglyceridemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017519028A JP2017519028A (ja) | 2017-07-13 |
| JP2017519028A5 true JP2017519028A5 (OSRAM) | 2018-08-02 |
Family
ID=53511030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575073A Withdrawn JP2017519028A (ja) | 2014-06-26 | 2015-06-25 | 重度の高トリグリセリド血症の処置 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150374649A1 (OSRAM) |
| EP (1) | EP3160458A1 (OSRAM) |
| JP (1) | JP2017519028A (OSRAM) |
| KR (1) | KR20170020514A (OSRAM) |
| CN (1) | CN106470675A (OSRAM) |
| AU (1) | AU2015279905A1 (OSRAM) |
| BR (1) | BR112016028918A2 (OSRAM) |
| CA (1) | CA2951280A1 (OSRAM) |
| CL (1) | CL2016003290A1 (OSRAM) |
| EA (1) | EA201790091A1 (OSRAM) |
| HK (1) | HK1231380A1 (OSRAM) |
| IL (1) | IL249757A0 (OSRAM) |
| MX (1) | MX2016017081A (OSRAM) |
| PH (1) | PH12016502415A1 (OSRAM) |
| SG (1) | SG11201610243YA (OSRAM) |
| WO (1) | WO2015200580A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| ES2701094T3 (es) | 2014-03-20 | 2019-02-20 | Cymabay Therapeutics Inc | Tratamiento de enfermedades colestáticas intrahepáticas |
| KR102374499B1 (ko) | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| SG11202005850VA (en) * | 2017-12-21 | 2020-07-29 | Kowa Co | Methods of treatment of hypertrigl yceridemia |
| WO2021097034A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases |
| WO2021097027A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of alcoholic liver disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1667964T3 (da) | 2003-09-19 | 2009-10-26 | Janssen Pharmaceutica Nv | 4-((Phenoxyalkyl)thio)-phenoxyeddikesyrer og analoger |
| JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| ES2586127T3 (es) * | 2010-03-30 | 2016-10-11 | Novartis Ag | Usos de inhibidores de DGAT1 |
-
2015
- 2015-06-25 WO PCT/US2015/037596 patent/WO2015200580A1/en not_active Ceased
- 2015-06-25 CN CN201580033722.XA patent/CN106470675A/zh active Pending
- 2015-06-25 AU AU2015279905A patent/AU2015279905A1/en not_active Abandoned
- 2015-06-25 BR BR112016028918A patent/BR112016028918A2/pt not_active Application Discontinuation
- 2015-06-25 MX MX2016017081A patent/MX2016017081A/es unknown
- 2015-06-25 US US14/749,934 patent/US20150374649A1/en not_active Abandoned
- 2015-06-25 KR KR1020177002016A patent/KR20170020514A/ko not_active Withdrawn
- 2015-06-25 CA CA2951280A patent/CA2951280A1/en not_active Abandoned
- 2015-06-25 EP EP15734013.4A patent/EP3160458A1/en not_active Withdrawn
- 2015-06-25 SG SG11201610243YA patent/SG11201610243YA/en unknown
- 2015-06-25 HK HK17105013.3A patent/HK1231380A1/zh unknown
- 2015-06-25 JP JP2016575073A patent/JP2017519028A/ja not_active Withdrawn
- 2015-06-25 EA EA201790091A patent/EA201790091A1/ru unknown
-
2016
- 2016-12-02 PH PH12016502415A patent/PH12016502415A1/en unknown
- 2016-12-22 CL CL2016003290A patent/CL2016003290A1/es unknown
- 2016-12-25 IL IL249757A patent/IL249757A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519028A5 (OSRAM) | ||
| CN104981253B (zh) | 固溶体组合物及其在慢性炎症中的用途 | |
| JP2017513836A5 (OSRAM) | ||
| JP7053478B2 (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| JP2017505285A5 (OSRAM) | ||
| JP2013521310A5 (OSRAM) | ||
| JP2015511638A5 (OSRAM) | ||
| JP2009530398A5 (OSRAM) | ||
| JP2017528471A (ja) | 肝疾患を処置する方法 | |
| JP2016538277A5 (OSRAM) | ||
| JP2018162255A5 (OSRAM) | ||
| JP2018505158A5 (OSRAM) | ||
| JP2016538248A5 (OSRAM) | ||
| JP2015038155A5 (OSRAM) | ||
| JP2014505107A5 (OSRAM) | ||
| JP2017508817A5 (OSRAM) | ||
| JP2022031813A (ja) | １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| JP2016511753A5 (OSRAM) | ||
| JP2015508068A5 (OSRAM) | ||
| JP2019520344A5 (OSRAM) | ||
| IL318963A (en) | Compositions comprising 15-hydroxy-eicosapentaenoic acid and methods of using them | |
| JP2015522603A5 (OSRAM) | ||
| JP2016508996A5 (OSRAM) | ||
| JP2010510229A (ja) | 炎症性腸疾患のための治療方法 | |
| RU2019113150A (ru) | Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения |